Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Subscribe To Our Newsletter & Stay Updated